Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study
Authors:
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 16 (8) , 1403-1414
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Novartis
- Bristol-Myers Squibb
- Roche
- Boehringer Ingelheim
- Merck Sharp and Dohme United Kingdom
- Pfizer
- Science and Technology Commission of Shanghai Municipality (18DZ1910700, 18DZ1910702)
This publication has 29 references indexed in Scilit:
- Safety and dose modification for patients receiving niraparibAnnals of Oncology, 2018
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung CancerClinical Cancer Research, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- Successes and Challenges of PARP Inhibitors in Cancer TherapyFrontiers in Oncology, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free IntervalJournal of Clinical Oncology, 2010
- Functional Restoration of BRCA2 Protein by SecondaryBRCA2Mutations inBRCA2-Mutated Ovarian CarcinomaCancer Research, 2009